

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
KBROL.001CP1APPLICATION NO.  
09/991,433INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Broliden, et al.FILING DATE  
November 16, 2001GROUP  
1642

RECEIVED

AUG 29 2002

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
32	1.	4,612,337	09/16/86	Fox, Jr., et al.	523	113	05/30/85
32	2.	4,818,540	04/4/89	Chien, et al.	424	448	08/29/86
32	3.	4,908,773	03/13/90	Pantoliano, et al.	364	495	04/06/87
32	4.	5,288,707	02/22/94	Metternich	514	19	01/29/93
32	5.	5,508,186	04/16/96	Takashi, et al.	435	235	11/14/90
32	6.	5,552,534	09/03/96	Hirschmann, et al.	536	17.4	10/28/93
32	7.	5,811,515	09/22/98	Grubbs, et al.	530	330	05/29/96
32	8.	5,817,626	10/06/98	Findeis, et al.	514	12	03/14/95
32	9.	5,817,879	10/06/98	Hirschmann, et al.	568	333	08/26/96
32	10.	5,821,231	10/13/98	Arrhenius, et al.	514	18	06/05/95
32	11.	5,827,647	10/27/98	Young, et al.			
32	12.	5,874,529	02/23/99	Gilon, et al.	530	317	06/08/94
32	13.	5,916,563	06/29/99	Young, et al.			
32	14.	6,001,371	12/14/99	Young, et al.			
32	15.	6,132,732	10/17/00	Young, et al.			
32	16.	6,204,044	03/20/01	Brown			
32	17.	6,274,307	08/14/01	Soutschek, et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
32	18.	0 491 824 B1	05/10/95	EPO				
32	19.	WO 91/12269 A1	08/22/91	PCT (abstract in English)				X
32	20.	WO 91/04330 A	04/04/91	WIPO				

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
KBROL.001CP1APPLICATION NO.  
09/991,433INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Broliden, et al.FILING DATE  
November 16, 2001GROUP  
1642

RECEIVED

AUG 29 2002

TECH CENTER 1600/2900

EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- 32 21. Anderson and Young, Monographs in Virology, 20 (1997).
- 32 22. Armitage, "Emerging Applications of Recombinant Human...", Blood, Vol. 92, No. 12, pp. 4491-4508 (12/15/98).
- 32 23. Benet, et al., "Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination," The Pharmacological Basis of Therapeutics, 8<sup>th</sup> Ed., Goodman and Gilman's, pp. 3-32 (1990).
- 32 24. Bostic, et al., J. Infect. Dis., 179:619 (1999).
- 32 25. Brown, et al., J. Virol., 65:2702 (1991).
- 32 26. Brown, et al., Science, 262:114 (1993).
- 32 27. Burgess, et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of...", The Journal of Cell Biology, Vol. 111, pp. 2129-2138 (11/90).
- 32 28. Chipman, et al., "Cryo-electron microscopy studies of empty capsids of human parvovirus B19...", Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 7502-7506 (07/96).
- 32 29. Cotmore, et al., Science, 226:1161 (1984).
- 32 30. Ek, et al., "Colony Formation of Human Fetal CD34+ Hematopoietic Cells," Fetal Diagn. Ther., 11:326-334, 1996.
- 32 31. Ek, et al., "Cytokine Stimulation of Human Fetal Hematopoietic Cells," Fetal Diagn. Ther. 11:318-325, 1996.
- 32 32. Ek, et al., "Effects of cryopreservation on subsets of fetal liver cells," Bone Marrow Transplantation, 11:395-398, 1993.
- 32 33. Ek, et al., "Immunological capacity of human fetal liver cells," Bone Marrow Transplantation, 14:9-14, 1994.
- 32 34. Erdman, et al., J. Gen. Virol., 77:2767 (1996).
- 32 35. Farmer, et al., in TIPS, 9/82, pp. 362-365.
- 32 36. Fields, et al., Virology, Vol. 2, 3<sup>rd</sup> edition, Lippincott-Raven Pub., Philadelphia, PA, p. 2202, 2204, 2207 (1996).
- 32 37. Giralt, et al., Blood, 89:4531 (1997).
- 32 38. Jain, "Vascular and interstitial barriers to delivery of therapeutic agents in tumors," Cancer Metastasis Rev. 9(3):253-266, Nov. 1990.
- 32 39. Jain, "Delivery of Molecular Medicine to Solid Tumors," Science, Vol. 271, pp. 1079-1080, Feb. 23, 1996.
- 32 40. Kajigaya, et al., Proc. Natl. Acad. Sci. USA, 86:7601 (1989).
- 32 41. Kajigaya, et al., Proc. Natl. Acad. Sci. USA, 88:4646 (1991).
- 32 42. Kaltenbronn, et al., J. Med. Chem., 33:838-845 (1990).
- 32 43. Kemp, D.S., Tibech, "Peptidomimetics and the Template Approach to nucleation of beta-sheets and alpha-helices in Peptides", Vol. 8, pp. 249-255 (1990).
- 32 44. Lazar, et al., Molecular and Cellular Biology, 8(3):1247-1252, March 1988.
- 32 45. Le Blanc, et al., European Journal of Haematology 53:145-149, 1994.
- 32 46. Lindton, et al., "Mixed Lymphocyte Culture of Human Fetal Liver Cells," Fetal Diagn. Ther., 15:71-78, 2000.
- 32 47. Lindton, et al., "Recombinant Parvovirus B19 Empty Capsids Inhibit Fetal Hematopoietic Colony Formation in vitro," Fetal Diagn. Ther., 16:26-31, 2001.
- 32 48. Liu, et al., "Interleukin-6 and the Granulocyte Colony-Stimulating Factor Receptor Are Major Independent Regulators...", Blood, Vol. 90, No. 7, pp. 2583-2590, October 1, 1997.
- 32 49. Morey and Flemming, Br. J. Hematol., 82:302 (1992).

EXAMINER

DATE CONSIDERED

\*EXAMINER INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. KBROL.001CP1	APPLICATION NO. 09/991,433
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		<div style="text-align: right; font-size: 1.5em; font-weight: bold;">RECEIVED</div>	
		<div style="text-align: right; font-size: 1.2em;">AUG 29 2002</div>	
		FILING DATE November 16, 2001	GROUP 1642

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
32	50. Mortimer, et al., <u>Nature</u> , 302:426-429 (1983).
32	51. Ozawa, et al., <u>J. Virol.</u> , 62:2884 (1988).
32	52. Pabo, C.O., et al., <u>Biochemistry</u> , 25:5987-5991 (1986).
32	53. Perry, L.J. & Wetzel, R., <u>Science</u> , 226:555-557 (1984).
32	54. Rosenfeld, et al., <u>The Journal of Clinical Investigation</u> , 89:2023-2029, June 1992.
32	55. Shields, et al., "In Vitro Hematopoiesis is Inhibited in Humans and non-human Primates by Recombinant Parvo Virus Capsid," 20 <sup>th</sup> Annual Meeting of the Society for Maternal-Fetal Medicine, American Journal of Obstetrics and Gynecology, Vol. 181, No. 1, part 2, January 2002.
32	56. Slavin, et al., <u>Blood</u> , 91:756 (1998).
32	57. Verber, et al., in <u>TINS</u> , 9/85, pp. 392-396.
32	58. von dem Borne, et al., <u>Br. J. Hematol.</u> , 63:35-46 (1986).
32	59. Westgren, et al., <u>Am. J. Obstet. Gynecol.</u> , 176:49 (1996).

S:\DOCS\ESF\ESF-5516.DOC  
082202

COPY OF PAPERS  
ORIGINALLY FILED

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	2-19-03
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>			